VIDEO: SABCS includes ‘exciting’ new data in breast cancer
In this video, Sara Tolaney, MD, MPH, assistant professor of medicine at Harvard Medical School and a breast medical oncologist with Dana-Farber Cancer Institute, discusses research being presented at the symposium.
“At [San Antonio Breast Cancer Symposium] this year, I think there’s a lot of very exciting data that we’re going to see,” Tolaney said.
She noted that she is looking forward to seeing findings on elacestrant — a novel oral selective estrogen receptor degrader — compared with endocrine therapy among patients with metastatic, hormone receptor-positive breast cancer.
Tolaney also said she looked forward to hearing results from registration trials like the DESTINY-Breast03 trial, trials examining trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) among patients with breast cancer who developed brain metastases, immunotherapy trials — including KEYNOTE-522 and KETNOTE-355 — and “much more.”
References:
Bardia A, et al. GS2-02. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Cortes J, et al. GS1-02. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Schmid P, et al. GS1-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Collapse
Read more about